Pyxis Oncology announces acquisition of Apexigen; no deal terms disclosed

Pyxis Oncology, Inc.

Pyxis Oncology and Apexigen held a joint investor call on May 24, 2023 to discuss the proposed business combination.
Financial terms of the acquisition were not disclosed in the filing.
The transaction is subject to customary closing conditions, including stockholder and regulatory approvals.
Pyxis plans to file a registration statement on Form S-4 in connection with the deal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.